Advance to faster MRSA
and SA screening

Surveillance starts here

Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) infections represent a critical threat to public health. Staphylococcus aureus, commonly found in one third of the population, has now evolved resistance mechanisms due to frequent exposure to antibiotics in health care facilities. About 85% of invasive MRSA infections are identified as healthcare acquired,1 resulting in over 150,000 affected patients per year in Europe alone.2 Active surveillance can identify carriers with speed and accuracy, helping patients and healthcare institutions address infection challenges and escalating costs.

The cobas® MRSA/SA Nucleic acid test, for use on the cobas® Liat® System, provides an innovative solution for detecting both organism variances from a single nasal swab specimen, providing timesaving efficiencies and lifesaving answers in 30 minutes.

Speed where it matters
Results in under 30 minutes, quickly identifies colonized patients to aid in infection prevention; suitable for use in ER, ICU and STAT lab settings.

 

Simplified workflow
Less than 1 minute hands-on time, no vortex step, no precision pipetting, no result interpretation required.

 

Discrimination with PCR accuracy
High sensitivity and specificity with expanded strain inclusivity for MRSA and SA to detect new and emerging SCCmec subtypes including mecC.

 

MRSA3*

1

SA3*

2

*Compared to direct and enriched culture.

Intended use for cobas® MRSA/SA

The cobas® MRSA/SA Nucleic acid test for use on the cobas® Liat® System is an automated, real-time PCR assay for the rapid in vitro qualitative detection of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) DNA from nasal swabs to aid in the prevention and control of MRSA and SA infections in healthcare settings. The cobas® MRSA/SA Test is not intended to diagnose, guide or monitor treatment for MRSA or SA infections, or provide results of susceptibility to methicillin. A negative result does not preclude MRSA/SA nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiology typing or for further susceptibility testing.
CE-IVD cleared
This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Learn more about the expanding menus of assays.

CI=confidence intervals. LOD=limit of detection. CFU=colony-forming unit.

References: 1. Klevens RM, Morrison MA, Nadle J, et.al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Jama. 2007;298:1763-1771. 2. Köck R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, Mielke M, Peters G, Skov RL, Struelens MJ, Tacconelli E, Navarro Torné A, Witte W, Friedrich AW. Methicilin-resistant Staphylococcus aureus (MRSA): Burden of disease and control challenges in Europe. Euro Survello. 2010;15(41):pii-19688. 3. cobas® MRSA/SA [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2017.